A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker Selection

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker Selection

Background: Essential tremor (ET) is a common, progressive neurological syndrome with bilateral upper-limb dysfunction of at least 3-year duration, with or without tremor in other body locations. This disorder has a negative impact on daily function and quality of life. A single oral therapy has bee...

Full description

Bibliographic Details
Main Authors: Spyros Papapetropoulos, Margaret S. Lee, Stacey Boyer, Evan J. Newbold
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Neurology
Subjects:
essential tremor
CX-8998
T-type calcium channel modulator
proof of concept
TETRAS
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2019.00597/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2019.00597/full

Similar Items